Choosing the right survey: the lung cancer surgery

Cecilia Pompili, Michael Koller, Galina Velikova, Cecilia Pompili, Michael Koller, Galina Velikova

Abstract

Radical and palliative treatments for non-small cell lung cancer (NSCLC) have faced a significant evolution during last decades, which in turn has modified their effects on the patient quality of life (QoL). QoL data collection is becoming methodologically rigorous, with published recommendations and societal statements. In lung cancer surgery, there is no standardization in collecting and analyzing this outcome yet. However, to face the evolution in lung cancer therapies, few initiatives like the European Organization for the Research and Treatment of Cancer (EORTC) lung cancer module update project or the Patient-Reported Outcomes Measurement Information System (PROMIS), have now the potential to help thoracic surgeons to collect QoL data with validated dynamic instruments to make this outcome comparable to the clinical ones. This review aims to give an overview of the available and most commonly used QoL questionnaires in lung cancer surgery in order to facilitate future research and practical implementation.

Keywords: Quality of life (QoL); patient centered care; patient-reported outcomes (PROs); thoracic surgery.

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd.2019.12.131). The series “Patient reported Outcomes in Thoracic Surgery: A new Frontier” was commissioned by the editorial office without any funding or sponsorship. CP serves as an unpaid editorial board member of Journal of Thoracic Disease from Sep 2016 to Aug 2020. GV, MK and CP are members of the EORTC QoL group. The update of the lung cancer module and the Phase 4 study on the QLQ-LC29 have been funded by the EORTC. GV: reports personal fees from Roche, personal fees from Eisai, personal fees from Novartis, grants from Pfizer, grants from Breast Cancer NOW, grants from Yorkshire Cancer Research, grants from EORTC, outside the submitted work.

2020 Journal of Thoracic Disease. All rights reserved.

References

    1. Cornwell LD, Echeverria AE, Samuelian J, et al. Video-assisted thoracoscopic lobectomy is associated with greater recurrence-free survival than stereotactic body radiotherapy for clinical stage I lung cancer. J Thorac Cardiovasc Surg 2018;155:395-402. 10.1016/j.jtcvs.2017.07.065
    1. Gazala S, Pelletier JS, Storie D, et al. A systematic review and meta-analysis to assess patient-reported outcomes after lung cancer surgery. ScientificWorldJournal 2013;2013:789625. 10.1155/2013/789625
    1. Pompili C, Novoa N, Balduyck B. Clinical evaluation of quality of life: a survey among members of European Society of Thoracic Surgeons (ESTS). Interact Cardiovasc Thorac Surg 2015;21:415-9. 10.1093/icvts/ivv171
    1. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med 1995;41:1403-9. 10.1016/0277-9536(95)00112-K
    1. Bottomley A, Reijneveld JC, Koller M, et al. Current state of quality of life and patient-reported outcomes research. Eur J Cancer 2019;121:55-63. 10.1016/j.ejca.2019.08.016
    1. Calvert M, Kyte D, Mercieca-Bebber R, et al. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA 2018;319:483-94. 10.1001/jama.2017.21903
    1. Pe M, Dorme L, Coens C, et al. Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. Lancet Oncol 2018;19:e459-69. 10.1016/S1470-2045(18)30418-2
    1. U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research. U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research ; U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006;4:79. 10.1186/1477-7525-4-79
    1. Bottomley A, Pe M, Sloan J, et al. Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncol 2016;17:e510-4. 10.1016/S1470-2045(16)30510-1
    1. Sprangers MA, Cull A, Bjordal K, et al. The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC Study Group on Quality of Life. Qual Life Res 1993;2:287-95. 10.1007/BF00434800
    1. Juniper EF. Validated questionnaires should not be modified. Eur Respir J 2009;34:1015-7. 10.1183/09031936.00110209
    1. Pompili C, Brunelli A, Xiume F, et al. Prospective external convergence evaluation of two different quality-of-life instruments in lung resection patients. Eur J Cardiothorac Surg 2011;40:99-105. 10.1016/j.ejcts.2010.10.026
    1. Kuenstner S, Langelotz C, Budach V, et al. The comparability of quality of life scores. a multitrait multimethod analysis of the EORTC QLQ-C30, SF-36 and FLIC questionnaires. Eur J Cancer 2002;38:339-48. 10.1016/S0959-8049(01)00369-0
    1. Apolone G, Filiberti A, Cifani S, et al. Evaluation of the EORTC QLQ-C30 questionnaire: a comparison with SF-36 Health Survey in a cohort of Italian long-survival cancer patients. Ann Oncol 1998;9:549-57. 10.1023/A:1008264412398
    1. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83. 10.1097/00005650-199206000-00002
    1. Pompili C, Brunelli A. Quality of life after lung resection is not associated with functional objective measures. Eur Respir J 2013;42:283-5. 10.1183/09031936.00199212
    1. Brunelli A, Socci L, Refai M, et al. Quality of Life Before and After Major Lung Resection for Lung Cancer: A Prospective Follow-Up Analysis. Ann Thorac Surg 2007;84:410-6. 10.1016/j.athoracsur.2007.04.019
    1. Handy JJR, Asaph JW, Douville EC, et al. Does video-assisted thoracoscopic lobectomy for lung cancer provide improved functional outcomes compared with open lobectomy? Eur J Cardiothorac Surg 2010;37:451-5.
    1. Moller A, Sartipy U. Associations between changes in quality of life and survival after lung cancer surgery. J Thorac Oncol 2012;7:183-7. 10.1097/JTO.0b013e3182340abb
    1. Rizk NP, Ghanie A, Hsu M, et al. A Prospective Trial Comparing Pain and Quality of Life Measures After Anatomic Lung Resection Using Thoracoscopy or Thoracotomy. Ann Thorac Surg 2014;98:1160-6. 10.1016/j.athoracsur.2014.05.028
    1. EuroQol Group . EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208. 10.1016/0168-8510(90)90421-9
    1. EuroQol Research Foundation. EQ-5D-5L User Guide, 2019. Available online:
    1. Devlin NJ, Brooks R. EQ-5D and the EuroQol Group: Past, Present and Future. Appl Health Econ Health Policy 2017;15:127-37. 10.1007/s40258-017-0310-5
    1. Johnson JA, Pickard AS. Comparison of the EQ-5D and SF-12 health surveys in a general population survey in Alberta, Canada. Med Care 2000;38:115-21. 10.1097/00005650-200001000-00013
    1. Koide R, Kikuchi A, Miyajima M, et al. Quality assessment using EQ-5D-5L after lung surgery for non-small cell lung cancer (NSCLC) patients. Gen Thorac Cardiovasc Surg 2019;67:1056-61. 10.1007/s11748-019-01136-0
    1. Bejjani J, Fiore JF, Jr, Lee L, et al. Validity of the EuroQol-5 dimensions as a measure of recovery after pulmonary resection. J Surg Res 2015;194:281-8. 10.1016/j.jss.2014.11.016
    1. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76. 10.1093/jnci/85.5.365
    1. Osoba D, Zee B, Pater J, et al. Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 1994;3:353-64. 10.1007/BF00451727
    1. Nicklasson M, Bergman B. Validity, reliability and clinical relevance of EORTC QLQ-C30 and LC13 in patients with chest malignancies in a palliative setting. Qual Life Res 2007;16:1019-28. 10.1007/s11136-007-9210-8
    1. Pompili C, Velikova G, White J, et al. Poor preoperative patient-reported quality of life is associated with complications following pulmonary lobectomy for lung cancer†. Eur J Cardiothorac Surg 2017;51:526-31. 10.1093/ejcts/ezw363
    1. Balduyck B, Hendriks J, Lauwers P, et al. Quality of life evolution after lung cancer surgery: A prospective study in 100 patients. Lung Cancer 2007;56:423-31. 10.1016/j.lungcan.2007.01.013
    1. Schulte T, Schniewind B, Walter J, et al. Age-related impairment of quality of life after lung resection for non-small cell lung cancer. Lung Cancer 2010;68:115-20. 10.1016/j.lungcan.2009.05.019
    1. Burfeind WR, Jr, Tong BC, O'Branski E, et al. Quality of life outcomes are equivalent after lobectomy in the elderly. J Thorac Cardiovasc Surg 2008;136:597-604. 10.1016/j.jtcvs.2008.02.093
    1. Bendixen M, Jørgensen OD, Kronborg C, et al. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial. Lancet Oncol 2016;17:836-44. 10.1016/S1470-2045(16)00173-X
    1. Pompili C, Koller M, Velikova G, et al. EORTC QLQ-C30 summary score reliably detects changes in QoL three months after anatomic lung resection for Non-Small Cell Lung Cancer (NSCLC). Lung Cancer 2018;123:149-54. 10.1016/j.lungcan.2018.07.021
    1. Giesinger JM, Kieffer JM, Fayers PM, et al. Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. J Clin Epidemiol 2016;69:79-88. 10.1016/j.jclinepi.2015.08.007
    1. Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 1994;30A:635-42. 10.1016/0959-8049(94)90535-5
    1. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-9. 10.1200/JCO.1993.11.3.570
    1. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 2003;1:79. 10.1186/1477-7525-1-79
    1. Cella DF, Bonomi AE, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995;12:199-220. 10.1016/0169-5002(95)00450-F
    1. Cella D, Eton DT, Fairclough DL, et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 2002;55:285-95. 10.1016/S0895-4356(01)00477-2
    1. Luckett T, King MT, Butow PN, et al. Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Ann Oncol 2011;22:2179-90. 10.1093/annonc/mdq721
    1. Ring AE, Cheong KA, Watkins CL, et al. A Randomized Study of Electronic Diary versus Paper and Pencil Collection of Patient-Reported Outcomes in Patients with Non-Small Cell Lung Cancer. Patient 2008;1:105-13. 10.2165/01312067-200801020-00006
    1. Porter LS, Keefe FJ, Garst J, et al. Self-efficacy for managing pain, symptoms, and function in patients with lung cancer and their informal caregivers: associations with symptoms and distress. Pain 2008;137:306-15. 10.1016/j.pain.2007.09.010
    1. Videtic GMM, Reddy CA, Sorenson L. A prospective study of quality of life including fatigue and pulmonary function after stereotactic body radiotherapy for medically inoperable early-stage lung cancer. Support Care Cancer 2013;21:211-8. 10.1007/s00520-012-1513-9
    1. Hollen PJ, Gralla RJ, Kris MG, et al. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 1993;29A Suppl 1:S51-8. 10.1016/S0959-8049(05)80262-X
    1. Hollen PJ, Gralla RJ, Kris MG, et al. A comparison of visual analogue and numerical rating scale formats for the Lung Cancer Symptom Scale (LCSS): does format affect patient ratings of symptoms and quality of life? Qual Life Res 2005;14:837-47. 10.1007/s11136-004-0833-8
    1. Ferrero C, Badellino S, Filippi AR, et al. Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective study. Lung Cancer 2015;89:350-6. 10.1016/j.lungcan.2015.06.019
    1. Koller M, Warncke S, Hjermstad MJ, et al. Use of the lung cancer-specific Quality of Life Questionnaire EORTC QLQ-LC13 in clinical trials: A systematic review of the literature 20 years after its development. Cancer 2015;121:4300-23. 10.1002/cncr.29682
    1. Koller M, Hjermstad MJ, Tomaszewski KA, et al. An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients. Ann Oncol 2017;28:2874-81. 10.1093/annonc/mdx453
    1. 26th Annual Conference of the International Society for Quality of Life Research. Qual Life Res 2019;28:1-190. 10.1007/s11136-019-02257-y
    1. Kuliś D BA, Whittaker C, van de Poll-Franse LV, et al. The Use of the EORTC Item Library to Supplement EORTC Quality of Life Instruments. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European Congress; 2017 Nov 4-8; Glasgow, Scotland. 2017.
    1. Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol 2012;30:4249-55. 10.1200/JCO.2012.42.5967
    1. Garcia SF, Cella D, Clauser SB, et al. Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol 2007;25:5106-12. 10.1200/JCO.2007.12.2341
    1. Jones RS, Stukenborg GJ. Patient-Reported Outcomes Measurement Information System (PROMIS) Use in Surgical Care: A Scoping Study. J Am Coll Surg 2017;224:245-254.e1. 10.1016/j.jamcollsurg.2016.11.015
    1. Weinberger M, Oddone EZ, Samsa GP, et al. Are health-related quality-of-life measures affected by the mode of administration? J Clin Epidemiol 1996;49:135-40. 10.1016/0895-4356(95)00556-0
    1. Gundy CM, Aaronson NK. Effects of mode of administration (MOA) on the measurement properties of the EORTC QLQ-C30: a randomized study. Health Qual Life Outcomes 2010;8:35. 10.1186/1477-7525-8-35
    1. Velikova G, Brown JM, Smith AB, et al. Computer-based quality of life questionnaires may contribute to doctor-patient interactions in oncology. Br J Cancer 2002;86:51-9. 10.1038/sj.bjc.6600001
    1. Basch E, Deal AM, Kris MG, et al. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin Oncol 2016;34:557-65. 10.1200/JCO.2015.63.0830
    1. Pompili C, Franks KN, Brunelli A, et al. Patient reported outcomes following video assisted thoracoscopic (VATS) resection or stereotactic ablative body radiotherapy (SABR) for treatment of non-small cell lung cancer: protocol for an observational pilot study (LiLAC). J Thorac Dis 2017;9:2703-13. 10.21037/jtd.2017.07.35
    1. Khullar OV, Rajaei MH, Force SD, et al. Pilot Study to Integrate Patient Reported Outcomes After Lung Cancer Operations Into The Society of Thoracic Surgeons Database. Ann Thorac Surg 2017;104:245-53. 10.1016/j.athoracsur.2017.01.110
    1. Denis F, Basch E, Septans AL, et al. Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer. JAMA 2019;321:306-7. 10.1001/jama.2018.18085
    1. Avery KNL, Richards HS, Portal A, et al. Developing a real-time electronic symptom monitoring system for patients after discharge following cancer-related surgery. BMC Cancer 2019;19:463. 10.1186/s12885-019-5657-6

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera